Breast cancer, early stage
LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Giampaolo Bianchini, et al.
IO score, but not TNBCtype, is predictive of atezolizumab benefit over CT alone. Angiogenesis and lipid/glutamine metabolism were linked to resistance, suggesting new potential therapeutic targets. Super-responders in atezolizumab arm have a unique biology and represent ideal candidates to treatment de-escalation. Early biomarker dynamics provide additional predictive information.
120MO - Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Aranzazu Fernandez, et al.
In C40601 and PAMELA, multiple, mostly B-cell-related, iGES performed better than TILs for pCR prediction. In C40601, TILs did not provide additional RFS information to clinical parameters, subtype, and multiple GES. When both TILs and iGES are available, the prognostic value of RNA-based signatures is superior.
LBA13 - Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
Nadia Harbeck, et al.
In HER2+/HR+ EBC, tumor immunogenicity at baseline is associated with improved survival. Poor outcome associated with PIK3CAmut cannot be overcome by T-DM1. HER2+/HR+ tumors are driven by HER2 and ER; this heterogeneous biology needs
to be considered for future de-escalation concepts. Beyond pCR, trials in luminal A tumors should focus on survival as an endpoint.
LBA14 - Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
Sara A. Hurvitz, et al.
Interim analysis data demonstrated superior anti-proliferative activity of giredestrant compared with A. Safety was consistent with the known giredestrant profile.
121MO - Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial
Sofia Rivera, et al.
In women receiving locoregional RT, acute toxicities with a 3-week moderately hypofractionated regimen were mild and raised no important acute safety concerns. Further long-term follow-up is ongoing.
122MO - Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
José A. García-Saenz, et al.
In general, patient-reported QoL and fatigue was maintained during the study in both treatment arms. Statistically significant differences were observed between treatments in favor of the placebo arm; however, none were clinically relevant.
123MO - BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
Peter Schmid, et al.
Addition of IPAT to neoadjuvant atezo plus chemotherapy did not improve pCR rates. IPAT dose intensity was low due to increased toxicity.